| Document |
Document Title |
|
WO/2007/010976A1 |
[PROBLEMS] To inhibit the excess increase in body weight induced by various causes and to reduce the overweight. [MEANS FOR SOLVING PROBLEMS] Disclosed are: a composition comprising D-psicose for use in the inhibition of the excess incre...
|
|
WO/2007/010973A1 |
[PROBLEMS] To control neuropathic pain produced by various mechanisms. [MEANS FOR SOLVING PROBLEMS] Disclosed is a composition for elimination, relief or reduction of neuropathic pain comprising, as an active ingredient, at least one sub...
|
|
WO/2007/010975A1 |
[PROBLEMS] To prevent the progression occurrence or ameliorate a condition of obesity, diabetes or metabolic syndrome. [MEANS FOR SOLVING PROBLEMS] Disclosed is a composition comprising D-psicose and/or a derivative thereof as an active ...
|
|
WO/2007/010974A1 |
[PROBLEMS] To provide a composition having an effect of preventing the rapid increase in blood glucose level upon the intake of a carbohydrate and/or a sugar. [MEANS FOR SOLVING PROBLEMS] Disclosed is a composition comprising D-allose wh...
|
|
WO/2007/001283A2 |
A process for the synthesis of beta linked low molecular weight polymers of galactosamine and glucosamine has been developed. Through the use of high amounts of activating agents, efficient coupling of stable monomers is achieved. Using ...
|
|
WO/2007/001282A2 |
Compositions containing enriched populations of beta linked low molecular weight polymers of galactosamine and glucosamine are provided. The compositions are useful, for example, as antibacterial additives for food and other edible appli...
|
|
WO/2006/132310A1 |
It is intended to provide a liquid for preventing tissue adhesion which is easy to use due to the stability of covering condition during an operation and generally applicable to a surgical operation and a method of preventing tissue adhe...
|
|
WO/2006/130994A1 |
The syntheses and in vitro antitumor properties of carbamate-containing, dicarbamate-containing, and ureido-containing phospholipid compounds that have an ether linkage at the C-1 position of a glycerol backbone, a carbamate, dicarbamate...
|
|
WO/2006/131599A2 |
The present invention relates to a method of profiling a cell population comprising a step of detecting the presence or absence of at least two biological markers in said cell population, wherein at least one of said markers is a cell su...
|
|
WO/2006/126633A1 |
A process for the production of an organic compound having one or more free hydroxyl and/or thiol groups by subjecting an organic compound whose hydroxyl and/or thiol groups are at least partially acylated (hereinafter referred to as “...
|
|
WO/2006/126790A1 |
Provided are processes for preparing 6,7,8-trihydroxy-1-(hydroxymethyl)-3-oxo-2-oxa-4-azabicyclo[
3.3.1]nonane and processes for preparing valiolamine or its derivative using the same.
|
|
WO2006004748B1 |
An improved method for processing corn into ethanol and other valuable co-products. The invention generally involves a multi-step process which produces germ (or oil), protein, and feed yeast as its co-products while maintaining or enhan...
|
|
WO/2006/115136A1 |
It has been confirmed in tests in human that 1-kestose has an effect of increasing the production of an immunoglobulin A (IgA) antibody, an effect of inhibiting the production of an immunoglobulin E (IgE) antibody, an effect of activatin...
|
|
WO/2006/111783A1 |
The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds disorder herein can be useful for inhibition and prevention of inflammation and associated pathologies including inflammatory and auto...
|
|
WO/2006/112316A1 |
A method for the purification of cellobiose comprising the steps of: (A) preparing a cellobiose-containing sugar solution; (B) adjusting the content of cellobiose in the cellobiose-containing sugar solution to 50% by mass or more relativ...
|
|
WO/2006/104137A1 |
The invention provides a sucrase activity inhibitor and a glucoamylase activity inhibitor comprising one or more saccharides selected from the group consisting of palatinose, trehalose and reduced palatinose. Further, the invention provi...
|
|
WO/2006/100253A2 |
The invention relates to an enzymatic method for synthesizing oligosaccharides, whereby one saccharide group of a sucrose analogue each is transferred onto an acceptor molecule, for example for glycosylating a hydroxyl compound, a saccha...
|
|
WO/2006/101118A1 |
It is intended to provide a novel application of D-psicose (application to suppression of abnormal circadian increase in blood glucose level). It is a composition for suppressing abnormal circadian increase in plasma glucose level contai...
|
|
WO/2006/096963A1 |
The present invention relates to ionic liquids for use in chemical applications and capable of serving the dual function of solvent and liquid support. The ionic liquid lends itself to a method of synthesizing oligomers selected from the...
|
|
WO/2006/093364A1 |
Disclosed a method of producing sugar alcohols through the hydrogenation of sugars using a catalyst in which ruthenium is supported on a zirconia. The method includes hydrogenating sugar under relatively moderate reaction conditions usin...
|
|
WO/2006/086270A1 |
A process for forming lactose suitable for use in a pharmaceutical formulation comprises providing a plurality of lactose particles containing no more than 10% w/w of lactose particles having a volume average particle size of about 70 mi...
|
|
WO/2006/080430A1 |
An ophthalmic medicine composition, in particular, eye-drops, eye ointment, eyewash agent, intraocular perfusate, anterior chamber washing agent, internal medicine, injectable solution or extracted cornea preserving agent that excels in ...
|
|
WO/2006/070862A1 |
A process by which 5-deoxy-L-arabinose, which is important as a material for the production of saproterin, a useful therapeutic agent for atypical hyperphenylalaninemia, can be industrially and efficiently produced even with a simple pro...
|
|
WO/2006/070483A1 |
This invention provides a process for producing a DFA III crystal, characterized in that a solution containing difructose dianhydride III: DFA III, that is, a hardly digestive disaccharide comprising two fructose molecules bonded to each...
|
|
WO/2006/064078A1 |
The invention relates to a method of producing industrially-viable prebiotic oligosaccharides using a novel enzyme of Xanthophyllomyces dendrorhous, which is characterised by having $g(a)-glucosidase activity. The invention also relates ...
|
|
WO/2006/061396A1 |
The invention relates to a compound of general formula (I): where = 0 or 1, Z = O, S or CH2, R1 and R2 independently = OH or OY, where Y = a protecting group, OR3, where R3 = a monosaccharide or disaccharide group, A1-CH2-N+(CH3)3, X-, w...
|
|
WO2005092907B1 |
The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds disorder herein can be useful for inhibition and prevention of inflammation and associated pathologies including inflammatory and auto...
|
|
WO/2006/054429A1 |
An oral composition for potentiating the production of equol by an intestinal bacterium which contains, as the active ingredient, difructose anhydride for activating the equol productivity of the intestinal bacterium.
|
|
WO/2006/046738A1 |
A process for inexpensively producing an indigestible dextrin which contains an isomerized sugar and is highly useful in foods and beverages. This process comprises the following step (A) and at least one subsequent step selected between...
|
|
WO/2006/038613A1 |
It is considered that the excessive intake of sodium chloride is one of factors causative of the onset and worsening of diseases classified into life-style-related diseases and complications thereof. Thus, it is intended to provide a nov...
|
|
WO/2006/035725A1 |
A novel nonreducing sugar comprising glucose as a constituent sugar; a novel enzyme capable of expanding the room for choice of nonreducing sugar and forming the nonreducing sugar; a forming method and production process therefor; a DNA ...
|
|
WO/2006/026639A1 |
A process for the preparation of an alkoxylated sucrose ester including the steps of: forming an initial reaction mixture of a sucrose ester and from about 0.01% to about 5% of a catalyst; and forming an initial reaction product by react...
|
|
WO/2006/022325A1 |
It is intended to provide a novel and useful galactose derivative constituting a drug carrier by which a drug can be efficiently transported into the liver, a drug carrier containing this derivative and a medicinal composition containing...
|
|
WO/2006/021653A2 |
The invention concerns heparanase inhibiting compounds of general formula (I) wherein R represents a hydrogen atom, an hydroxyl radical, a -OSO3- radical, a -O-(C1-C5)alkyl radical or an -O- aralkyl radical; Z represents a COO- radical o...
|
|
WO/2006/017752A2 |
The invention relates to sulfated oligosaccharides, more particularly to new pharmaceutical uses of sulfated oligosaccharides. The invention provides a method of preventing, treating or alleviating the symptoms of acute and chronic', inf...
|
|
WO/2006/017727A2 |
The invention relates to new polysulfated glycosides of formula (I), the salts thereof formed with alkali metals or alkaline-earth metals, as well as the pharmaceutical compositions containing these compounds as active ingredients. Furth...
|
|
WO/2006/013193A2 |
Described herein are derivatives of arylsulfonamido-substituted hydroxamic acid of formula (I) having good solubility in water and inhibitory activity of matrix metalloproteinases, useful for the preparation of pharmaceutical composition...
|
|
WO/2006/012490A2 |
A novel ketogenic compound is provided having general formula (R(OCH(CH3)CH2C(O))nO)m-A wherein n is a integer between I and 10, m is an integer of 1 to 200,000, A is a monsaccharide, polysaccharide or oligosaccharide residue and R is se...
|
|
WO/2006/011713A1 |
1-&agr -halo-2,2-difluoro-2-deoxy-D-ribofuranose derivative of formula (I) having the 3-hydroxy group protected with a biphenylcarbonyl group is a solid which can be easily purified by a simple procedure such as recrystallization, and th...
|
|
WO/2006/011479A1 |
A process for producing a cellooligosaccharide which comprises enzymatically decomposing in the presence of a cellulase a water-insoluble natural cellulosic substance which has an average degree of polymerization of 700 or lower and an a...
|
|
WO/2006/009353A1 |
3R-carboxylate enantiomer derivative of formula (III) can be prepared easily and selectively by the method of the present invention, and a highly pure D-erythro-2,2-difluoro-2-deoxy-1-oxoribose derivative can be prepared efficiently from...
|
|
WO/2006/008379A1 |
The invention relates to a gene encoding a polypeptide exhibiting an endofucanase activity, i.e. an enzyme which degrades fucanes or fucoidans embodied in the form of polysaccharides formed by sulphated fucose units. A method for produci...
|
|
WO/2006/006267A1 |
An antistress agent which contains as an active ingredient a saccharide containing 3-O-&agr -D-glcopyranosyl-D-glucose as a structural unit. When used as a medicine, the antistress agent is free from side effects and can be taken habitua...
|
|
WO/2005/118609A2 |
Provided herein are small molecule stimulators of neuronal growth, their preparation, and their use for treatment of neurological disorders. In one embodiment, provided herein are methods of treatment, prevention, or amelioration of a va...
|
|
WO/2005/118607A1 |
Methods of making hyaluronates, including high molecular weight hyaluronates, are disclosed. The methods include contacting a hyaluronate-containing source with an acid to make an acidic hyaluronate suspension, contacting that suspension...
|
|
WO/2005/115408A1 |
[PROBLEMS] To find out a specific rare sugar having effects of inhibiting the proliferation of vascular endothelial cells and lumen formation and utilize these effects. To provide this rare sugar as a preventive/remedy for diseases with ...
|
|
WO/2005/115409A1 |
[PROBLEMS] To provide a composition for inhibiting the onset of arteriosclerosis by using a rare sugar D-psicose and an inhibition method. [MEANS FOR SOLVING PROBLEMS] A composition for inhibiting the onset of arteriosclerosis characteri...
|
|
WO/2005/113568A1 |
The present invention relates to novel galactosides and the use of the galactosides as a medicament, as well as for the manufacture of a medicament for treatment of disorders relating to the binding of galactin to receptors in a mammal. ...
|
|
WO/2005/107798A1 |
The present invention relates to Neisserial Lipo-Oligo-Saccharides (LOS) that comprise a tri-saccharide outer core that shows increased binding to the DC-SIGN receptor on dendritic cells, as a result of which the Neisserial LOS’s of th...
|
|
WO/2005/103276A1 |
A process comprising causing β-fructofuranosidase derived from a microbe belonging to the genus Bacillus and sucrose unassimilating yeast to act on an aqueous solution containing sucrose and lactose to thereby produce a sugar with a hig...
|
